GLP-1 Weight Loss Cardiovascular Evidence: Meta-Analysis Review
Intragastric balloon therapy obesity is a meaningful treatment option for patients not ready for surgery or pharmacotherapy. This therapy offers short-term weight reduction comparable to semaglutide 2.4 mg weekly. Understanding this evidence helps…
Strategies for Muscle Preservation During GLP-1 Therapy
Muscle preservation during GLP-1 receptor agonist therapy is critical to avoid excessive lean mass loss. This page discusses strategies to maintain muscle while benefiting from GLP-1 treatments. Clinicians should emphasize resistance training and…
Medical Cannabis for Orthopaedic Pain: Promising Signal, Weak Evidence Base
Medical cannabis orthopedic pain is a growing area of patient interest despite limited high-quality evidence. This review highlights promising signals for musculoskeletal conditions but notes weak study designs. Clinicians should consider cannabis as…
Tirzepatide vs Semaglutide: Weight & Muscle Loss Outcomes
This article reviews tirzepatide vs semaglutide weight loss clinical evidence, highlighting differences in muscle loss outcomes. Tirzepatide shows greater total weight loss but may increase lean mass depletion compared to semaglutide. Understanding these…
Comparing Clinical Evidence of GLP-1 Receptor Agonists
GLP-1 receptor agonist clinical evidence drug comparisons reveal important sex-based differences in obesity outcomes. Understanding these differences helps tailor weight management strategies. Genetic factors also influence individual responses to GLP-1…
Clinical Evidence on Dietary Fiber and GLP-1 Receptor Agonists
Dietary fiber GLP-1 receptor agonist effects are emerging as a complementary approach in metabolic health. This evidence highlights the potential role of fermentable fibers in appetite regulation. Family medicine clinicians should consider dietary fiber…
Medicinal Cannabis Doesn’t Help Anxiety, Depression, or PTSD, Huge Review Finds
A large systematic review found limited evidence for cannabis in treating mental health disorders such as anxiety, depression, and PTSD. This challenges the widespread use of medicinal cannabis for these psychiatric conditions. Clinicians should…
GLP-1 Receptor Agonist Evidence: Weight Loss & Marriage Risk
GLP-1 receptor agonist psychosocial outcomes are important for understanding the effects of weight loss on relationships. Significant weight loss can lead to shifts in self-perception and interpersonal dynamics. Clinicians should consider counseling…
Medical Cannabis for Chronic Pain: Promise, Pharmacology, and Persistent Gaps
This 2025 medical cannabis chronic pain review examines the pharmacology and clinical evidence for cannabinoids in pain management. While promising, significant gaps remain in standardized dosing and long-term safety data. The review highlights the need…
Acute and Long-Term Psychiatric Consequences of Synthetic Cannabinoids and Related Novel Psychoactive Substances: A Systematic Review
This systematic review examines psychiatric consequences synthetic cannabinoids cause, highlighting both acute and long-term effects. Synthetic cannabinoids present significant psychiatric risks distinct from natural cannabis. Understanding these…